Skip to main content
Premium Trial:

Request an Annual Quote

MDS Proteomics Names New CFO, Eyes IPO in 02

NEW YORK, Dec. 11 - MDS Proteomics on Tuesday has named Anil K. Amlani to be its chief financial officer.


According to the company, he will be responsible for "driving and maintaining further financial growth and development" and will report directly to Frank Gleeson, MDS Proteomics' president and CEO.


"Anil's financial expertise, his strong relationships with the investment and analyst community, and his established technology background will play an essential role in helping MDS Proteomics to determine financing opportunities, including the possibility of an IPO in 2002," Gleeson said in a statement.


"Anil will also assist us greatly in our ongoing negotiations with top-tier pharmaceutical and biotechnology companies concerning broad commercial collaborations," he added.


Before joining Toronto-based MDS Proteomics, Amlani was senior vice president and CFO of Cancom, Canadian Satellite Communications where he headed business planning and financing for all operating units and oversaw all principal investments.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.